Expected probabilities of response by outcome for key comparators
| Intervention* | Probability of response, median (95% credible interval) | ||||
| PASI 75 | PASI 90 | Resolution of enthesitis | Resolution of dactylitis | Discontinuation due to AEs | |
| Brodalumab 210 mg | 70.3% (62.3, 77.4) | 52.7% (44, 61.3) | 38% (24.9, 52.6) | 53.6% (38.5, 70.6) | 1.4% (0.2, 7.2) |
| Ixekizumab 80 mg every two weeks | 67% (57.8, 75.5) | 49% (39.4, 58.9) | 40.5% (26.7, 56.3) | 59.8% (36.3, 77.4) | 3.9% (1, 14.5) |
| Ixekizumab 80 mg every four weeks† | 63.1% (55.4, 70.3) | 44.9% (37.1, 52.7) | 33.1% (21.5, 46.8) | 63.2% (41.7, 78.2) | 2.1% (0.6, 7.8) |
| Secukinumab 150 mg† | 53.2% (45.7, 59.5) | 35% (28.3, 41.1) | 41.6% (29.6, 53.7) | 50.5% (35.8, 67.2) | 2.3% (0.6, 8.2) |
| Secukinumab 300 mg† | 63.7% (56.3, 69.5) | 45.4% (37.9, 51.9) | 44.4% (32, 56.7) | 62.4% (47.4, 77.1) | 1.9% (0.6, 6.5) |
| Guselkumab 100 mg every eight weeks‡ | 76.6% (68.5, 82.2) | 60.3% (50.7, 67.5) | 42.3% (28.1, 56.3) | 60.4% (42.4, 73.8) | 1.9% (0.4, 8.4) |
| Tildrakizumab 100 mg every twelve weeks | 40.2% (25.5, 55.1) | 23.7% (13, 36.8) | – | – | 11.8% (0.4, 98.3) |
| Ustekinumab 45 mg‡ | 60% (52.8, 67.8) | 41.6% (34.6, 49.9) | 32.9% (21.1, 49.9) | 43.9% (29.5, 62.2) | 0.6% (0.1, 2.9) |
| Ustekinumab 90 mg | 54.8% (46.6, 63)* | 36.5% (29.1, 44.8)* | 40.4% (27.2, 57.9)† | 46.8% (32, 65)† | 0.7% (0.1, 3.2) |
| Adalimumab 40 mg every two weeks† | 44.2% (36.9, 50.7) | 27% (21.2, 32.8) | 39.7% (27.6, 52.6) | 51.3% (33.3, 68.1) | 3.8% (1.2, 11.8) |
| Certolizumab 200 mg every two weeks | 42.2% (31, 53) | 25.4% (16.8, 34.8) | – | – | 5.2% (0.7, 36.8) |
| Certolizumab 400 mg every four weeks | 41.5% (30, 53.3) | 24.8% (16.1, 35.2) | – | – | 8.2% (1.2, 47.4) |
| Etanercept 50 mg once weekly | 26.1% (15.4, 42.2) | 13.5% (6.8, 25.4) | – | – | 2.6% (0.1, 48.7) |
| Etanercept 50 mg +MTX 20 mg once weekly | – | – | – | – | 3.3% (0.1, 56.7) |
| Etanercept 50 mg twice weekly | 33.9% (20.1, 52.5) | 18.9% (9.6, 34.3) | – | – | 4.2% (0.1, 63.1) |
| Golimumab 50 mg | 43.5% (32.1, 58.4) | 26.5% (17.6, 40) | – | – | 0.8% (0.1, 6.4) |
| Golimumab 100 mg | 55.7% (44, 69.6) | 37.4% (26.9, 52) | – | – | 0.8% (0.1, 6.4) |
| Infliximab 5 mg/kg | 65.8% (54.7, 78) | 47.7% (36.4, 62) | – | – | 8.2% (1.3, 47) |
| Infliximab 5 mg/kg+MTX 15 mg | – | – | – | – | 12.4% (0.2, 89.9) |
| Abatacept 125 mg‡ | 16.3% (10.4, 23.9) | 7.4% (4.2, 12) | 33.9% (20, 51.8) | 43.1% (25.2, 62.3) | 0.6% (0, 7.2) |
| Placebo† | 9.7% (3.4, 22) | 3.9% (1.1, 10.8) | 23% (12.7, 37.8) | 31.1% (11, 62.3) | 2.4% (0.8, 7.1) |
*Key comparators include bDMARDs at doses licensed for use in PsA or PsO.
†Based on a combination of studies reporting outcomes at week 12 or 16 and week 24.
‡Based on studies reporting outcomes at week 24 only bDMARD.
AE, adverse event; bDMARD, biological disease-modifying antirheumatic drug; MTX, methotrexate; PASI, Psoriasis Area and Severity Index; PsA, psoriatic arthritis; PsO, psoriasis.